Do DSM Classifications Help or Hinder drug Development? 

Overview

Journal Dialogues Clin Neurosci

Specialty Neurology

Date 2020 Jul 24

PMID 32699507

Citations 4

Authors

Michael Davidson

Cristian Gabos-Grecu

Affiliations

Soon will be listed here.

Abstract

Development and regulatory approval of psychotropic drugs targets individuals with syndromes described in the current Diagnostic and Statistical Manual of Mental Disorders (DSM). This helps drug developers and regulators to communicate with prescribers, and prescribers to match a specific psychotropic with the individual patient(s) most likely to benefit from it. However, this practice has been criticized on the grounds that DSM syndromes are too heterogenous biologically, and the effects of psychotropics are too nonspecific to allow for an effective match. This review considers the advantages and disadvantages of the current practice and the possible alternatives. It concludes that efforts should be made to explore psychotropic development transdiagnostically, free of the DSM boundaries. However, currently there exists no alternative diagnostic system that is clearly superior to the DSM in terms of communications between the stakeholders in drug development. .

Citing Articles

Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence.

Davidson M, Carpenter Jr W Schizophr Bull. 2023; 50(1):14-21.

PMID: 37929893 PMC: 10754173. DOI: 10.1093/schbul/sbad145.

Cortisol and the Dexamethasone Suppression Test as a Biomarker for Melancholic Depression: A Narrative Review.

Schumacher M, Santambrogio J J Pers Med. 2023; 13(5).

PMID: 37241007 PMC: 10223878. DOI: 10.3390/jpm13050837.

Revisiting the seven pillars of RDoC.

Morris S, Sanislow C, Pacheco J, Vaidyanathan U, Gordon J, Cuthbert B BMC Med. 2022; 20(1):220.

PMID: 35768815 PMC: 9245309. DOI: 10.1186/s12916-022-02414-0.

Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development.

Strauss G, Bartolomeo L, Harvey P NPJ Schizophr. 2021; 7(1):16.

PMID: 33637748 PMC: 7910596. DOI: 10.1038/s41537-021-00145-4.

References

Tome M, Isaac M . A regulatory view on novel methodologies and context of use of biomarkers. Neurosci Biobehav Rev. 2018; 97:94-95. DOI: 10.1016/j.neubiorev.2018.09.015. View

Dean C . Psychopharmacology: a house divided. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 35(1):1-10. DOI: 10.1016/j.pnpbp.2010.08.028. View

Davis K, Kahn R, Ko G, Davidson M . Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991; 148(11):1474-86. DOI: 10.1176/ajp.148.11.1474. View

Davidson M . Cognitive impairment as a diagnostic criterion and treatment target in schizophrenia. World Psychiatry. 2019; 18(2):171-172. PMC: 6502436. DOI: 10.1002/wps.20651. View

Kendell R, Jablensky A . Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry. 2002; 160(1):4-12. DOI: 10.1176/appi.ajp.160.1.4. View

Strauss G, Cohen A . A Transdiagnostic Review of Negative Symptom Phenomenology and Etiology. Schizophr Bull. 2017; 43(4):712-719. PMC: 5472109. DOI: 10.1093/schbul/sbx066. View

Corcoran C, Wong M, OKeane V . Bupropion in the management of apathy. J Psychopharmacol. 2004; 18(1):133-5. DOI: 10.1177/0269881104043284. View

Starkstein S, Pahissa J . Apathy following traumatic brain injury. Psychiatr Clin North Am. 2014; 37(1):103-12. DOI: 10.1016/j.psc.2013.10.002. View

Scherer R, Drye L, Mintzer J, Lanctot K, Rosenberg P, Herrmann N . The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018; 19(1):46. PMC: 5774109. DOI: 10.1186/s13063-017-2406-5. View

10.

Husain M, Roiser J . Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci. 2018; 19(8):470-484. DOI: 10.1038/s41583-018-0029-9. View

11.

Ruthirakuhan M, Herrmann N, Abraham E, Chan S, Lanctot K . Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018; 5:CD012197. PMC: 6494556. DOI: 10.1002/14651858.CD012197.pub2. View

12.

Moncrieff J . Research on a 'drug-centred' approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs. Epidemiol Psychiatr Sci. 2017; 27(2):133-140. PMC: 6998955. DOI: 10.1017/S2045796017000555. View

13.

Hirschfeld R . History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000; 61 Suppl 6:4-6. View

14.

Papassotiropoulos A, de Quervain D . Failed drug discovery in psychiatry: time for human genome-guided solutions. Trends Cogn Sci. 2015; 19(4):183-7. DOI: 10.1016/j.tics.2015.02.002. View

15.

Caeiro L, Ferro J, Costa J . Apathy secondary to stroke: a systematic review and meta-analysis. Cerebrovasc Dis. 2013; 35(1):23-39. DOI: 10.1159/000346076. View

16.

Weiser M, Reichenberg A, Rabinowitz J, Knobler H, Lubin G, Yazvitzky R . Cognitive performance of male adolescents is lower than controls across psychiatric disorders: a population-based study. Acta Psychiatr Scand. 2004; 110(6):471-5. DOI: 10.1111/j.1600-0447.2004.00385.x. View

17.

Reichenberg A, Velthorst E, Davidson M . Cognitive impairment and psychosis in schizophrenia: independent or linked conditions?. World Psychiatry. 2019; 18(2):162-163. PMC: 6502409. DOI: 10.1002/wps.20644. View

18.

Kendler K . From Many to One to Many-the Search for Causes of Psychiatric Illness. JAMA Psychiatry. 2019; 76(10):1085-1091. DOI: 10.1001/jamapsychiatry.2019.1200. View

19.

Moritz S, Gaweda L, Heinz A, Gallinat J . Four reasons why early detection centers for psychosis should be renamed and their treatment targets reconsidered: we should not catastrophize a future we can neither reliably predict nor change. Psychol Med. 2019; 49(13):2134-2140. DOI: 10.1017/S0033291719001740. View

20.

Clarke D, Narrow W, Regier D, Kuramoto S, Kupfer D, Kuhl E . DSM-5 field trials in the United States and Canada, Part I: study design, sampling strategy, implementation, and analytic approaches. Am J Psychiatry. 2012; 170(1):43-58. DOI: 10.1176/appi.ajp.2012.12070998. View

Do DSM Classifications Help or Hinder drug Development?

Do DSM Classifications Help or Hinder drug Development? 